Key result
Growth hormone therapy in Japanese patients with adult growth hormone deficiency was well tolerated, with 16.8% of patients experiencing adverse drug reactions, and effectively improved lipid metabolism.
Why the study?
Does long-term somatropin therapy improve lipid profiles and maintain safety in Japanese patients with adult growth hormone deficiency?
Population
334 Japanese patients with severe adult growth hormone deficiency, mean age 47.6 years. Includes both…
Design
Cohort
Follow-up
mean 3.1 ± 1.3 years (range 2 to 5 years)
Authors
Loading...
Supports somatropin tolerability and lipid benefits in Japanese AGHD; hypothesis-generating and requires randomized confirmation before practice change.
Observational (n=334)
Yes
Does long-term somatropin therapy improve lipid profiles and maintain safety in Japanese patients with adult growth hormone deficiency?
Long-term somatropin therapy in Japanese patients with adult growth hormone deficiency is well-tolerated and improves lipid profiles without significantly worsening glucose metabolism.
Shimatsu et al. (2017) conducted an observational in Adult growth hormone deficiency (AGHD) (n=334). Growth hormone (Norditropin) was evaluated on Adverse drug reactions (ADRs). Growth hormone therapy in Japanese patients with adult growth hormone deficiency was well tolerated, with 16.8% of patients experiencing adverse drug reactions, and effectively improved lipid metabolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: